JMP Securities Begins Coverage on Astria Therapeutics (NASDAQ:ATXS)

JMP Securities assumed coverage on shares of Astria Therapeutics (NASDAQ:ATXS) in a report issued on Friday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $26.00 target price on the biotechnology company’s stock.

ATXS has been the subject of a number of other reports. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, January 23rd. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $25.67.

Astria Therapeutics Stock Up 4.9 %

ATXS stock opened at $7.86 on Friday. Astria Therapeutics has a 52-week low of $7.16 and a 52-week high of $16.90. The company has a market capitalization of $443.57 million, a PE ratio of -3.76 and a beta of 0.70. The stock’s 50 day moving average is $8.93 and its two-hundred day moving average is $10.43.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ATXS. Quest Partners LLC boosted its position in Astria Therapeutics by 180.8% during the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,798 shares during the period. New York State Common Retirement Fund boosted its position in Astria Therapeutics by 67.0% during the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 4,300 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Astria Therapeutics during the 4th quarter worth $107,000. PDT Partners LLC acquired a new position in Astria Therapeutics during the 3rd quarter worth $140,000. Finally, SG Americas Securities LLC acquired a new position in Astria Therapeutics during the 3rd quarter worth $155,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.